SKSaara Kortelainen

Saara Kortelainen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Saara Kortelainen has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Localized scleroderma and related comorbidities: a single-centre cohort study

    by Saara Kortelainen, Niina Hieta, Tiia Rissanen, Johanna Paltta, Laura Pirilä, Veli-Matti Kähäri

    Background: Localized scleroderma, or morphoea, is a rare autoimmune disease that affects the skin and underlying tissue. It is more common in girls and women than in boys and men. The incidence has two peaks: one in childhood and another in middle-age. Concomitant autoimmune diseases are frequently observed, whereas systemic sclerosis occurs rarely simultaneously. Objectives: To assess the clinical features, comorbidities and treatments of localized scleroderma in Southwest Finland. Methods: Patients diagnosed with localized scleroderma (International Classification of Diseases, 10th Revision code L94) treated between 1 January 2005 and 30 November 2020 were identified from the hospital discharge register of Turku University Hospital, Turku, Finland. Diagnoses were classified into five main types and their subtypes based on the European Dermatology Forum criteria. Basic demographic data, associated comorbidities, and treatments used and their efficacy were recorded. Results: A total of 155 people with morphoea were included, with 125 female patients (80.6%) and 30 male patients (19.4%). The most common subtype was limited, plaque-type morphoea (n = 71; 45.8%), followed by the generalized type (n = 57; 36.8%). Fifty-nine concomitant autoimmune diseases were identified in 45 patients (29.0%), most frequently autoimmune thyroid diseases (n = 23; 14.8%). Simultaneous systemic sclerosis was rare (n = 3; 1.9%). The most common malignancy was breast cancer (n = 11; 7.1%). Extracutaneous manifestations were more common in patients with paediatric-onset morphoea (n = 4/27; 14.8%) vs. those with adult-onset disease (n = 2/122; 1.6%). The most commonly used systemic treatment was methotrexate (n = 25; 16.1%), which was beneficial for 64% of the treated patients (n = 16). Phototherapy was administered in 63 of 155 patients (40.6%) and was beneficial in 49 (78%). Conclusions: At our centre, patients with morphoea often require systemic immunomodulatory treatment or phototherapy. The incidence of the generalized subtype and the occurrence of concomitant autoimmune diseases, particularly thyroid autoimmune diseases, is relatively high. No evidence of an increased risk of malignancy was found in these patients.


  • Causes and predictors of death among Finnish patients with systemic sclerosis

    by S Kortelainen, M Käyrä, T Rissanen, J Paltta, K Taimen, L Pirilä, J Huhtakangas

    ObjectiveThe aim of this study was to assess causes and predictors of death among Finnish patients with systemic sclerosis (SSc).MethodMedical records of patients registered with the ICD-10 code M34 from 1996 to 2018 in two university hospitals were reviewed retrospectively. Clinical data were collected until the end of 2020. Death certificates were obtained from Statistics Finland up to August 2021. Using death certificates and patient records, the cause of death for each patient was determined. The mean age at death, median time from SSc diagnosis, and factors predicting death were analysed.ResultsAmong 313 SSc patients, 91 deaths occurred between April 2000 and September 2020. Overall 5 and 10 year survival rates were 88.4% and 80.2%, respectively. SSc was the most common primary cause of death (n = 35) and interstitial lung disease (ILD) was the most common SSc-related cause of death (n = 13). Moreover, 52% of the patients with diffuse SSc and 33% of those with limited cutaneous SSc died as a result of SSc itself. Patients who died because of SSc were significantly younger [mean +/- sd age 65.6 +/- 12.7 years, 95% confidence interval (CI) 61.2-70.1] than those who died from other causes (74.2 +/- 9.6 years, 95% CI 71.5-76.9) (p = 0.0006). ILD, pulmonary arterial hypertension, gastrointestinal involvement, male gender, and older age at disease onset predicted death.ConclusionThe disease itself was the major cause of death among Finnish SSc patients, in both diffuse and limited forms of SSc.


  • Systemic sclerosis: changes in the incidence rates in the Finnish population during the years 1999–2018

    by S Kortelainen, M Käyrä, S Hurme, J Paltta, L Pirilä, J Huhtakangas

    ObjectiveThe aim of our study was to examine changes in the incidence of systemic sclerosis (SSc) in Finland using two different classification criteria.MethodMedical records of patients who had been registered with ICD-10 code M34 from 1999 to 2018 in two university hospitals were reviewed retrospectively. This period was divided into 5 year periods: 1999-2003, 2004-2008, 2009-2013, and 2014-2018. Using American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2013 criteria and clinical findings, we reclassified patients into four groups: diffuse SSc, limited SSc, sine SSc, or early SSc. In the same population, we also investigated whether the ACR 1980 criteria were fulfilled.ResultsIn 1999-2018, 246 new patients with SSc and 45 patients with early SSc were identified using ACR/EULAR 2013 criteria. Of these patients, 70 fulfilled the ACR 1980 criteria. Using ACR/EULAR 2013 criteria, the increase in new diagnoses was statistically significant when comparing the fourth period with the first period (p = 0.0012). The increase was due to a rise in limited SSc. Mean annual incidence rates in these groups were 0.9, 1.2, 1.9, and 2.8 per 100 000 inhabitants & GE; 16 years old. An increasing trend was also seen when using ACR 1980 criteria, but this was not statistically significant.ConclusionThe incidence of SSc increased during the period between 1999-2003 and 2014-2018 using ACR/EULAR 2013, but not using ACR 1980 criteria. The increase was detected within a limited SSc subclass, owing to more sensitive classification criteria.


  • Open Access

    Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis

    by J. Hiltunen, P. Parmanne, T. Sokka, T. Lamberg, P. Isomäki, O. Kaipiainen-Seppänen, R. Peltomaa, T. Uutela, L. Pirilä, K. Taimen, et al.

    Key messages: Considerable proportion of patients with SpA have been immunized to the subcutaneous anti-TNF drug they are using. Concomitant use of MTX protects from immunization, whereas SASP does not. Patients with SpA using subcutaneous anti-TNF drugs can benefit from monitoring of the drug trough levels. Immunization to biological drugs can lead to decreased efficacy and increased risk of adverse effects. The objective of this cross-sectional study was to assess the extent and significance of immunization to subcutaneous tumor necrosis factor (TNF) inhibitors in axial spondyloarthritis (axSpA) patients in real-life setting. A serum sample was taken 1–2 days before the next drug injection. Drug trough concentrations, anti-drug antibodies (ADAb) and TNF-blocking capacity were measured in 273 patients with axSpA using subcutaneous anti-TNF drugs. The clinical activity of SpA was assessed using the Bath AS Disease Activity Index (BASDAI) and the Maastricht AS Entheses Score (MASES). ADAb were found in 11% of the 273 patients: in 21/99 (21%) of patients who used adalimumab, in 0/83 (0%) of those who used etanercept, in 2/79 (3%) of those who used golimumab and in 6/12 (50%) of those who used certolizumab pegol. Use of methotrexate reduced the risk of formation of ADAb, whereas sulfasalazine did not. Presence of ADAb resulted in decreased drug concentration and reduced TNF-blocking capacity. However, low levels of ADAb had no effect on TNF-blocking capacity and did not correlate with disease activity. The drug trough levels were below the consensus target level in 36% of the patients. High BMI correlated with low drug trough concentration. Patients with low drug trough levels had higher disease activity. The presence of anti-drug antibodies was associated with reduced drug trough levels, and the patients with low drug trough levels had higher disease activity. The drug trough levels were below target level in significant proportion of patients and, thus, measuring the drug concentration and ADAb could help to optimize the treatment in SpA patients.